0      0


SES303 - Bridging the Translational Gap: Wheeler Bio’s Journey in Digitalized CDMO Services


‐ Jan 30, 2024 10:30am

Wheeler Bio, a new boutique CDMO (Contract Development and Manufacturing Organization) specializing in early clinical phase drug development, aims to offer comprehensive development and manufacturing services to bridge the translational gap between preclinical stages and IND (Investigational New Drug) filing. Wheeler Bio accelerates the development of manufacturing processes that are ready for commercialization in a cost-effective manner by embracing digitalization and the principles of Pharma 4.0. This presentation delves into Wheeler's journey from conception, design, construction, to operational readiness, with a focus on the seamless integration of digitalization, equipment connectivity, and infrastructure for future digital twinning.